stockrow
Friday 6 November 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
33.04
0.57
+1.76%
Follow HRMY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.77 | 11.63 | 11.12 | 13.61 |
+8 more quarters Free account |
P/S ratio |
2.32 | 2.20 | 1.80 | 2.48 | |
P/FCF ratio |
8.11 | 6.70 | 5.37 | 6.99 | |
P/Operating CF |
29.90 | 22.82 | 58.34 | 17.05 | |
P/B ratio |
2.14 | 2.11 | 1.78 | 2.47 | |
Price to Tangible BV |
2.29 | 2.29 | 1.96 | 2.76 | |
EV/Sales |
1.69 | 1.66 | 1.27 | 1.77 | |
EV/EBITDA |
6.86 | 6.25 | 5.31 | 6.61 | |
EV/Operating CF |
5.17 | 4.49 | 3.33 | 4.42 | |
EV/FCF |
5.91 | 5.07 | 3.77 | 5.00 | |
Quick Ratio |
3.31 | 3.33 | 3.45 | 3.46 | |
Current Ratio |
3.44 | 3.48 | 3.58 | 3.60 | |
Net Debt/EBITDA |
(10.44) | (5.41) | (11.16) | (13.34) | |
Debt/Assets |
10.09% | 11.21% | 12.49% | 12.87% | |
Debt/Equity |
0.14 | 0.15 | 0.17 | 0.19 | |
Asset Turnover |
0.74 | 0.77 | 0.77 | 0.76 | |
Operating CF/Net income |
1.59 | 1.23 | 0.85 | 5.61 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.01) | |
Interest Coverage |
17.71 | 29.09 | 11.53 | 10.87 | |
Research and Development Expense of Revenue |
26.65% | 17.83% | 32.21% | 20.48% | |
Selling, General and Administrative Expense of Revenue |
23.19% | 23.79% | 29.81% | 35.58% | |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
2.99% | 3.57% | 4.93% | 4.09% | |
Graham Net Nets |
0.23 | 0.21 | 0.26 | 0.24 | |
Graham Number |
35.64 | 34.85 | 29.88 | 30.60 | |
Earnings Yield |
7.83% | 8.60% | 9.00% | 7.35% | |
Free Cash Flow Yield |
12.33% | 14.92% | 18.63% | 14.31% | |
Revenue per Share |
4.60 | 4.51 | 3.73 | 4.24 | |
Operating CF per Share |
1.31 | 1.60 | 0.48 | 2.19 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
1.31 | 1.60 | 0.48 | 2.19 | |
Cash per Share |
13.20 | 11.53 | 11.08 | 13.49 | |
Shareholders Equity per Share |
18.36 | 17.25 | 15.74 | 15.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.36 | 17.25 | 15.74 | 15.14 | |
Free Cash Flow |
76.69 | 92.43 | 27.76 | 126.04 | |
Working Capital |
663.29 | 580.26 | 561.48 | 654.88 | |
Capital Expenditures |
— | — | — | (0.11) | |
Net Current Asset Value |
528.82 | 440.49 | 417.34 | 505.60 | |
EV/EBIT |
7.62 | 6.92 | 6.00 | 7.39 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
10.45 | 9.15 | 8.55 | 10.32 | |
| Other line items | |||||
Average Receivables |
114.20 | 101.99 | 107.10 | 89.91 | |
Average Payables |
26.63 | 24.99 | 23.03 | 15.72 | |
Average Inventory |
6.38 | 6.23 | 5.83 | 6.28 | |
Average Assets |
1,343.23 | 1,240.55 | 1,163.68 | 1,135.42 | |
Average Common Equity |
953.68 | 886.16 | 815.44 | 764.69 |
Columns are period end dates · fundamentals updated 6 Nov 2026